# Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US

> **NCT03282240** · PHASE3 · COMPLETED · sponsor: **Sanofi Pasteur, a Sanofi Company** · enrollment: 2670 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** QIV-HD
- **BIOLOGICAL:** Licensed TIV-HD1
- **BIOLOGICAL:** Investigational TIV-HD2

## Key facts

- **NCT ID:** NCT03282240
- **Lead sponsor:** Sanofi Pasteur, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-08
- **Primary completion:** 2017-11-02
- **Final completion:** 2018-04-19
- **Target enrollment:** 2670 (ACTUAL)
- **Last updated:** 2022-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03282240

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03282240, "Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03282240. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*